U.S. FDA grants Priority Review for spesolimab for the treatment of flares in patients with generalized pustular psoriasis (GPP), a rare, life-threatening skin disease

/PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and...

Related Keywords

Prnewswire Boehringer Ingelheim ,Christopher Wahlers ,Matt Frankel ,Boehringer Ingelheim Pharmaceuticals ,Animal Health ,Boehringer Ingelheim ,Drug Administration ,Clinical Development ,Biologics License Application ,Priority Review ,Orphan Drug Designation ,Breakthrough Therapy Designation ,Vice President ,Medical Affairs ,Specialty Care ,Ingelheim Immunology ,Pioneering Science ,Human Pharma ,Biopharmaceutical Contract ,